“
TL;DR
The central result was a significant change in serum aCGRP levels, but not VIP levels, in response to the treatment.
PLOS ONE · 11 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result was a significant change in serum aCGRP levels, but not VIP levels, in response to the treatment.
This was a longitudinal pilot study of 21 pediatric cystic fibrosis (CF) patients recruited at the onset of a pulmonary exacerbation. Serum VIP and aCGRP levels were measured via ELISA at three time points: hospital admission, three days post-antibiotic, and two weeks post-antibiotic therapy. Serum VIP levels were significantly associated with the presence of diabetes mellitus (p = 0.026), other comorbidities (p = 0.013), and the type of antibiotic therapy (p = 0.019). Serum aCGRP levels were associated with antibiotic type (p = 0.012) and a positive Staphylococcus aureus test (p = 0.046). Limitations noted by the authors include a small sample size, lack of standardized treatments, and the absence of pulmonary function test data. The study concludes that serum aCGRP shows potential as a biomarker for response to therapy, warranting further investigation in larger studies.